Therapeutic modulators of STAT signalling for human diseases (original) (raw)
Bromberg, J. & Darnell, J. E. Jr. The role of STATs in transcriptional control and their impact on cellular function. Oncogene19, 2468–2473 (2000). CASPubMed Google Scholar
Darnell, J. E. Jr. STATs and gene regulation. Science277, 1630–1635 (1997). CASPubMed Google Scholar
Adamkova, L., Souckova, K. & Kovarik, J. Transcription protein STAT1: biology and relation to cancer. Folia Biol.53, 1–6 (2007). CAS Google Scholar
Szabo, S. J. et al. Molecular mechanisms regulating Th1 immune responses. Annu. Rev. Immunol.21, 713–758 (2003). CASPubMed Google Scholar
Meraz, M. A. et al. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK–STAT signaling pathway. Cell84, 431–442 (1996). CASPubMed Google Scholar
Agrawal, S. et al. Signal transducer and activator of transcription 1 is required for optimal foam cell formation and atherosclerotic lesion development. Circulation115, 2939–2947 (2007). CASPubMed Google Scholar
Liu, L. et al. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J. Exp. Med.208, 1635–1648 (2011). CASPubMedPubMed Central Google Scholar
van de Veerdonk, F. L. et al. STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N. Engl. J. Med.365, 54–61 (2011). CASPubMed Google Scholar
Gamero, A. M. et al. STAT2 contributes to promotion of colorectal and skin carcinogenesis. Cancer Prev. Res.3, 495–504 (2010). CAS Google Scholar
Takeda, K. et al. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc. Natl Acad. Sci. USA94, 3801–3804 (1997). CASPubMed Google Scholar
Akira, S. Functional roles of STAT family proteins: lessons from knockout mice. Stem Cells17, 138–146 (1999). A comprehensive review of the knowledge gained from STAT-knockout mice. CASPubMed Google Scholar
Takeda, K. et al. Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice. J. Immunol.161, 4652–4660 (1998). CASPubMed Google Scholar
Sano, S. et al. Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. EMBO J.18, 4657–4668 (1999). CASPubMedPubMed Central Google Scholar
Macias, E., Rao, D. & Digiovanni, J. Role of STAT3 in skin carcinogenesis: insights gained from relevant mouse models. J. Skin Cancer2013, 684050 (2013). PubMedPubMed Central Google Scholar
Darnell, J. E. Validating Stat3 in cancer therapy. Nature Med.11, 595–596 (2005). CASPubMed Google Scholar
Jing, N. & Tweardy, D. J. Targeting Stat3 in cancer therapy. Anticancer Drugs16, 601–607 (2005). CASPubMed Google Scholar
Yu, H. & R. Jove, The STATs of cancer — new molecular targets come of age. Nature Rev. Cancer4, 97–105 (2004). CAS Google Scholar
Buettner, R., Mora, L. B. & Jove, R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin. Cancer Res.8, 945–954 (2002). CASPubMed Google Scholar
Turkson, J. & Jove, R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene19, 6613–6626 (2000). CASPubMed Google Scholar
Yue, P. & Turkson, J. Targeting STAT3 in cancer: how successful are we? Expert Opin. Investig. Drugs18, 45–56 (2009). CASPubMedPubMed Central Google Scholar
Turkson, J. STAT proteins as novel targets for cancer drug discovery. Expert Opin. Ther. Targets.8, 409–422 (2004). CASPubMed Google Scholar
Kortylewski, M. et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nature Med.11, 1314–1321 (2005). CASPubMed Google Scholar
Wang, T. et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nature Med, 10, 48–54 (2004). This paper proves that STAT3 signalling negatively influences the antitumour activity of tumour-infiltrating immune cells. PubMed Google Scholar
Siddiquee, K. et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc. Natl Acad. Sci. USA104, 7391–7396 (2007). CASPubMed Google Scholar
Siddiquee, K. A. et al. An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 stability and processing and induces antitumor cell effects. ACSChem. Biol.2, 787–798 (2007). CAS Google Scholar
Sen, M. et al. Lack of toxicity of a STAT3 decoy oligonucleotide. Cancer Chemother. Pharmacol.63, 983–995 (2009). CASPubMed Google Scholar
Niu, G. et al. Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res,59, 5059–5063 (1999). This study demonstrates for the first time that STAT3 is a valid anticancer therapeutic target, as a dominant-negative STAT3 variant significantly inhibits tumour growth in a melanoma xenograft mouse model. CAS Google Scholar
Turkson, J. et al. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J. Biol. Chem,276, 45443–45455 (2001). This study describes the first inhibitor of a STAT protein, which is a designed peptide that can successfully suppress STAT3 signalling. CAS Google Scholar
Holland, S. M. et al. STAT3 mutations in the hyper-IgE syndrome. N. Engl. J. Med.357, 1608–1619 (2007). CASPubMed Google Scholar
Koskela, H. L. et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N. Engl. J. Med,366, 1905–1913 (2012). This study identifies mutations within the STAT3 SH2 domain in patients with large granular lymphocytic leukaemia, causing STAT3 hyperactivation. CAS Google Scholar
Mogensen, T. H., Jakobsen, M. A. & Larsen, C. S. Identification of a novel STAT3 mutation in a patient with hyper-IgE syndrome. Scand. J. Infect. Dis.45, 235–238 (2013). PubMed Google Scholar
Lovett-Racke, A. E., Yang, Y. & Racke, M. K. Th1 versus Th17: are T cell cytokines relevant in multiple sclerosis? Biochim. Biophys. Acta1812, 246–251 (2011). CASPubMed Google Scholar
Chitnis, T. et al. Effect of targeted disruption of STAT4 and STAT6 on the induction of experimental autoimmune encephalomyelitis. J. Clin. Invest.108, 739–747 (2001). CASPubMedPubMed Central Google Scholar
Menke, J. et al. Targeting transcription factor Stat4 uncovers a role for interleukin-18 in the pathogenesis of severe lupus nephritis in mice. Kidney Int.79, 452–463 (2011). CASPubMed Google Scholar
Lin, J. X. & Leonard, W. J. The role of Stat5a and Stat5b in signaling by IL-2 family cytokines. Oncogene19, 2566–2576 (2000). CASPubMed Google Scholar
Buitenhuis, M. et al. Signal transducer and activator of transcription 5a (STAT5a) is required for eosinophil differentiation of human cord blood-derived CD34+ cells. Blood.101, 134–142 (2003). CASPubMed Google Scholar
Udy, G. B. et al. Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. Proc. Natl Acad. Sci. USA94, 7239–7244 (1997). CASPubMed Google Scholar
Imada, K. et al. Stat5b is essential for natural killer cell-mediated proliferation and cytolytic activity. J. Exp. Med.188, 2067–2074 (1998). CASPubMedPubMed Central Google Scholar
Nelson, E. A. et al. The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood117, 3421–3429 (2011). CASPubMedPubMed Central Google Scholar
Cotarla, I. et al. Stat5a is tyrosine phosphorylated and nuclear localized in a high proportion of human breast cancers. Int. J. Cancer108, 665–671 (2004). CASPubMed Google Scholar
Shuai, K. et al. Constitutive activation of STAT5 by the BCR_–_ABL oncogene in chronic myelogenous leukemia. Oncogene13, 247–254 (1996). CASPubMed Google Scholar
Benekli, M., Baumann, H. & Wetzler, M. Targeting signal transducer and activator of transcription signaling pathway in leukemias. J. Clin. Oncol.27, 4422–4432 (2009). CASPubMedPubMed Central Google Scholar
Nelson, E. A. et al. A chemical biology approach to developing STAT inhibitors: molecular strategies for accelerating clinical translation. Oncotarget2, 518–524 (2011). PubMedPubMed Central Google Scholar
Hou, J. et al. An interleukin-4-induced transcription factor: IL-4 Stat. Science265, 1701–1706 (1994). CASPubMed Google Scholar
Sehra, S. et al. IL-4 regulates skin homeostasis and the predisposition toward allergic skin inflammation. J. Immunol.184, 3186–3190 (2010). CASPubMedPubMed Central Google Scholar
Chapoval, S. P. et al. STAT6 expression in multiple cell types mediates the cooperative development of allergic airway disease. J. Immunol.186, 2571–2583 (2011). CASPubMedPubMed Central Google Scholar
Kuperman, D. A. & Schleimer, R. P. Interleukin-4, interleukin-13, signal transducer and activator of transcription factor 6, and allergic asthma. Curr. Mol. Med.8, 384–392 (2008). CASPubMedPubMed Central Google Scholar
Chiba, Y. et al. Interleukin-13 augments bronchial smooth muscle contractility with an up-regulation of RhoA protein. Am. J. Respir. Cell. Mol. Biol.40, 159–167 (2009). CASPubMed Google Scholar
Chiba, Y. et al. A novel STAT6 inhibitor AS1517499 ameliorates antigen-induced bronchial hypercontractility in mice. Am. J. Respir. Cell. Mol. Biol.41, 516–524 (2009). CASPubMed Google Scholar
Khaled, W. T. et al. The IL-4/IL-13/Stat6 signaling pathway promotes luminal mammary epithelial cell development. Development134, 2739–2750 (2007). CASPubMed Google Scholar
O'Shea, J. J., Holland, S. M. & Staudt, L. M. JAKs and STATs in immunity, immunodeficiency, and cancer. N. Engl. J. Med.368, 161–170 (2013). CASPubMed Google Scholar
Quintas-Cardama, A. & Verstovsek, S. Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance. Clin. Cancer Res.19, 1933–1940 (2013). CASPubMedPubMed Central Google Scholar
Turkson, J. et al. Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol. Cancer Ther.3, 261–269 (2004). CASPubMed Google Scholar
Coleman, D. R. et al. Investigation of the binding determinants of phosphopeptides targeted to the SRC homology 2 domain of the signal transducer and activator of transcription 3. Development of a high-affinity peptide inhibitor. J. Med. Chem.48, 6661–6670 (2005). CASPubMed Google Scholar
Ren, Z. et al. Identification of a high-affinity phosphopeptide inhibitor of Stat3. Bioorg. Med. Chem. Lett.13, 633–636 (2003). CASPubMed Google Scholar
Gunning, P. T. et al. Isoform selective inhibition of STAT1 or STAT3 homo-dimerization via peptidomimetic probes: structural recognition of STAT SH2 domains. Bioorg. Med. Chem. Lett.17, 1875–1878 (2007). CASPubMed Google Scholar
McMurray, J. S., Structural basis for the binding of high affinity phosphopeptides to Stat3. Biopolymers90, 69–79 (2008). CASPubMed Google Scholar
Zhao, W. Jaganathan, S. & Turkson, J. A cell-permeable Stat3 SH2 domain mimetic inhibits Stat3 activation and induces antitumor cell effects in vitro. J. Biol. Chem.285, 35855–35865 (2010). CASPubMedPubMed Central Google Scholar
Chen, J. et al. Structure-based design of conformationally constrained, cell-permeable STAT3 inhibitors. ACSMed. Chem. Lett.1, 85–89 (2010). Google Scholar
Mandal, P. K. et al. Potent and selective phosphopeptide mimetic prodrugs targeted to the Src homology 2 (SH2) domain of signal transducer and activator of transcription 3. J. Med. Chem.54, 3549–3563 (2011). CASPubMedPubMed Central Google Scholar
Auzenne, E. J. et al. A phosphopeptide mimetic prodrug targeting the SH2 domain of Stat3 inhibits tumor growth and angiogenesis. J. Exp. Ther. Oncol.10, 155–162 (2012). CASPubMedPubMed Central Google Scholar
Song, H. et al. A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc. Natl Acad. Sci. USA102, 4700–4705 (2005). CASPubMed Google Scholar
Fuh, B. et al. LLL-3 inhibits STAT3 activity, suppresses glioblastoma cell growth and prolongs survival in a mouse glioblastoma model. Br. J. Cancer100, 106–112 (2009). CASPubMedPubMed Central Google Scholar
Hao, W. et al. Discovery of the catechol structural moiety as a Stat3 SH2 domain inhibitor by virtual screening. Bioorg. Med. Chem. Lett.18, 4988–4992 (2008). CASPubMed Google Scholar
Zhang, X. et al. A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes. Biochem. Pharmacol.79, 1398–1409 (2010). CASPubMedPubMed Central Google Scholar
Zhang, X. et al. Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc. Natl Acad. Sci. USA109, 9623–9628 (2012). CASPubMed Google Scholar
Zhang, X. et al. A novel inhibitor of STAT3 homodimerization selectively suppresses STAT3 activity and malignant transformation. Cancer Res.73, 1922–1933 (2013). CASPubMedPubMed Central Google Scholar
Xu, X. et al. Chemical probes that competitively and selectively inhibit Stat3 activation. PLoS ONE4, e4783 (2009). PubMedPubMed Central Google Scholar
Dave, B. et al. Selective small molecule Stat3 inhibitor reduces breast cancer tumor-initiating cells and improves recurrence free survival in a human-xenograft model. PLoS ONE7, e30207 (2012). CASPubMedPubMed Central Google Scholar
Schust, J. et al. Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem. Biol.13, 1235–1242 (2006). CAS Google Scholar
Ashizawa, T. et al. Antitumor activity of a novel small molecule STAT3 inhibitor against a human lymphoma cell line with high STAT3 activation. Int. J. Oncol.38, 1245–1252 (2011). CASPubMed Google Scholar
Matsuno, K. et al. Identification of a new series of STAT3 inhibitors by virtual screening. ACSMed. Chem. Lett.1, 371–3755 (2010). CAS Google Scholar
Chen, H. et al. Fragment-based drug design and identification of HJC0123, a novel orally bioavailable STAT3 inhibitor for cancer therapy. Eur. J. Med. Chem. 62C, 498–507 (2013). CASPubMedPubMed Central Google Scholar
Zhang, M. et al. Identification and characterization of small molecule inhibitors of signal transducer and activator of transcription 3 (STAT3) signaling pathway by virtual screening. Bioorg. Med. Chem. Lett.23, 2225–2229 (2013). CASPubMed Google Scholar
Kim, M. J. et al. OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells. Cancer Lett.335, 145–152 (2013). CASPubMed Google Scholar
Yang, C. L. et al. Curcumin blocks small cell lung cancer cells migration, invasion, angiogenesis, cell cycle and neoplasia through Janus kinase–STAT3 signaling pathway. PLoS ONE7, e37960 (2012). CASPubMedPubMed Central Google Scholar
Tu, S. P. et al. Curcumin induces the differentiation of myeloid-derived suppressor cells and inhibits their interaction with cancer cells and related tumor growth. Cancer Prev. Res.5, 205–215 (2012). CAS Google Scholar
Fossey, S. L. et al. The novel curcumin analog FLLL32 decreases STAT3 DNA binding activity and expression, and induces apoptosis in osteosarcoma cell lines. BMC Cancer11, 112 (2011). CASPubMedPubMed Central Google Scholar
Selvendiran, K. et al. HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition. Cancer Biol. Ther.12, 837–845 (2011). CASPubMed Google Scholar
Tierney, B. J. et al. HO-3867, a STAT3 inhibitor induces apoptosis by inactivation of STAT3 activity in BRCA1-mutated ovarian cancer cells. Cancer Biol. Ther.13, 766–775 (2012). CASPubMed Google Scholar
Lin, L. et al. Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. Cancer Res.70, 2445–2454 (2010). CASPubMedPubMed Central Google Scholar
Onimoe, G. I. et al. Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice. Invest. New Drugs30, 916–926 (2012). CASPubMed Google Scholar
Lin, L. et al. A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells. Mol. Cancer9, 217 (2010). CASPubMedPubMed Central Google Scholar
Bill, M. A. et al. Structurally modified curcumin analogs inhibit STAT3 phosphorylation and promote apoptosis of human renal cell carcinoma and melanoma cell lines. PLoS ONE7, e40724 (2012). CASPubMedPubMed Central Google Scholar
Nam, S. et al. Novel synthetic derivatives of the natural product berbamine inhibit Jak2/Stat3 signaling and induce apoptosis of human melanoma cells. Mol. Oncol.6, 484–493 (2012). CASPubMedPubMed Central Google Scholar
Zhang, X. et al. Indirubin inhibits tumor growth by antitumor angiogenesis via blocking VEGFR2-mediated JAK/STAT3 signaling in endothelial cell. Int. J. Cancer129, 2502–2511 (2011). CASPubMed Google Scholar
Nam, S. et al. Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells. Proc. Natl Acad. Sci. USA102, 5998–6003 (2005). CASPubMed Google Scholar
Liu, L. et al. A novel 7-bromoindirubin with potent anticancer activity suppresses survival of human melanoma cells associated with inhibition of STAT3 and Akt signaling. Cancer Biol. Ther.13, 13 (2012). CAS Google Scholar
Nam, S. et al. Dual inhibition of Janus and Src family kinases by novel indirubin derivative blocks constitutively-activated Stat3 signaling associated with apoptosis of human pancreatic cancer cells. Mol. Oncol.7, 369–378 (2013). CASPubMed Google Scholar
Shakibaei, M., Harikumar, K. B. & Aggarwal, B. B. Resveratrol addiction: to die or not to die. Mol. Nutr. Food Res.53, 115–128 (2009). CASPubMed Google Scholar
Li, T. et al. Evaluation of anti-leukemia effect of resveratrol by modulating STAT3 signaling. Int. Immunopharmacol.10, 18–25 (2010). CASPubMed Google Scholar
Kim, J. E. et al. LYR71, a derivative of trimeric resveratrol, inhibits tumorigenesis by blocking STAT3-mediated matrix metalloproteinase 9 expression. Exp. Mol. Med.40, 514–522 (2008). CASPubMedPubMed Central Google Scholar
Yang, Y. P. et al. Resveratrol suppresses tumorigenicity and enhances radiosensitivity in primary glioblastoma tumor initiating cells by inhibiting the STAT3 axis. J. Cell. Physiol.227, 976–993 (2012). CASPubMed Google Scholar
Gupta, S. C. et al. Chemosensitization of tumors by resveratrol. Ann. NY Acad. Sci.1215, 150–160 (2011). CASPubMed Google Scholar
Piotrowska, H. Kucinska, M. & Murias, M. Biological activity of piceatannol: leaving the shadow of resveratrol. Mutat. Res.750, 60–82 (2012). CASPubMed Google Scholar
Santandreu, F. M. et al. Resveratrol potentiates the cytotoxic oxidative stress induced by chemotherapy in human colon cancer cells. Cell Physiol. Biochem.28, 219–228 (2011). CASPubMed Google Scholar
Lin, C. L. et al. Protective effect of caffeic acid on paclitaxel induced anti-proliferation and apoptosis of lung cancer cells involves NF-κB pathway. Int. J. Mol. Sci.13, 6236–6245 (2012). CASPubMedPubMed Central Google Scholar
Jung, J. E. et al. Caffeic acid and its synthetic derivative CADPE suppress tumor angiogenesis by blocking STAT3-mediated VEGF expression in human renal carcinoma cells. Carcinogenesis28, 1780–1787 (2007). CASPubMed Google Scholar
Kong, L. Y. et al. Inhibition of p-STAT3 enhances IFN-α efficacy against metastatic melanoma in a murine model. Clin. Cancer Res.16, 2550–2561 (2010). CASPubMedPubMed Central Google Scholar
Sai, K. et al. Induction of cell-cycle arrest and apoptosis in glioblastoma stem-like cells by WP1193, a novel small molecule inhibitor of the JAK2/STAT3 pathway. J. Neurooncol.107, 487–501 (2012). CASPubMed Google Scholar
Lee, H. K. et al. Capsaicin inhibits the IL-6/STAT3 pathway by depleting intracellular gp130 pools through endoplasmic reticulum stress. Biochem. Biophys. Res. Commun.382, 445–450 (2009). CASPubMed Google Scholar
Shin, D. S. et al. Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells. Cancer Res.69, 193–202 (2009). CASPubMed Google Scholar
Walker, S. R. et al. Microtubule-targeted chemotherapeutic agents inhibit signal transducer and activator of transcription 3 (STAT3) signaling. Mol. Pharmacol.78, 903–908 (2010). CASPubMed Google Scholar
Kannaiyan, R. et al. Celastrol inhibits proliferation and induces chemosensitization through down-regulation of NF-κB and STAT3 regulated gene products in multiple myeloma cells. Br. J. Pharmacol.164, 1506–1521 (2011). CASPubMedPubMed Central Google Scholar
Rajendran, P. et al. Celastrol suppresses growth and induces apoptosis of human hepatocellular carcinoma through the modulation of STAT3/JAK2 signaling cascade in vitro and in vivo. Cancer Prev. Res.5, 631–643 (2012). CAS Google Scholar
Zhang, C. et al. Avicin D selectively induces apoptosis and downregulates p-STAT-3, BCL-2, and survivin in cutaneous T-cell lymphoma cells. J. Invest. Dermatol.128, 2728–2735 (2008). CASPubMed Google Scholar
Lee, J., Hahm, E. R. & Singh, S. V. Withaferin A inhibits activation of signal transducer and activator of transcription3 in human breast cancer cells. Carcinogenesis31, 1991–1998 (2010). CASPubMedPubMed Central Google Scholar
Um, H. J. et al. Withaferin A inhibits JAK/STAT3 signaling and induces apoptosis of human renal carcinoma Caki cells. Biochem. Biophys. Res. Commun.427, 24–29 (2012). CASPubMed Google Scholar
Pandey, M. K., Sung, B. & Aggarwal, B. B. Betulinic acid suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase SHP-1 in human multiple myeloma cells. Int. J. Cancer127, 282–292 (2010). CASPubMedPubMed Central Google Scholar
Pathak, A. K. et al. Ursolic acid inhibits STAT3 activation pathway leading to suppression of proliferation and chemosensitization of human multiple myeloma cells. Mol. Cancer Res.5, 943–955 (2007). CASPubMed Google Scholar
Shanmugam, M. K. et al. Ursolic acid inhibits multiple cell survival pathways leading to suppression of growth of prostate cancer xenograft in nude mice. J. Mol. Med.89, 713–727 (2011). CASPubMed Google Scholar
Honda, T. et al. Synthetic oleanane and ursane triterpenoids with modified rings A and C: a series of highly active inhibitors of nitric oxide production in mouse macrophages. J. Med. Chem.43, 4233–4246 (2000). CASPubMed Google Scholar
Duan, Z. et al. CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cells. Cancer Chemother. Pharmacol.63, 681–689 (2009). CASPubMed Google Scholar
Ryu, K. et al. Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of Stat3 pathway. BMC Cancer10, 187 (2010). CASPubMedPubMed Central Google Scholar
Tran, K. et al. The synthetic triterpenoid CDDO-methyl ester delays estrogen receptor-negative mammary carcinogenesis in polyoma middle T mice. Cancer Prev. Res.5, 726–734 (2012). CAS Google Scholar
Blaskovich, M. A. et al. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res.63, 1270–1279 (2003). CASPubMed Google Scholar
Hsu, H. S. et al. Cucurbitacin I inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancer-derived CD133-positive cells. Cancer117, 2970–2985 (2011). CASPubMed Google Scholar
Chang, C. J. et al. Inhibition of phosphorylated STAT3 by cucurbitacin I enhances chemoradiosensitivity in medulloblastoma-derived cancer stem cells. ChildsNerv. Syst.28, 363–373 (2012). Google Scholar
Tseng, L. M. et al. Targeting signal transducer and activator of transcription 3 pathway by cucurbitacin I diminishes self-renewing and radiochemoresistant abilities in thyroid cancer-derived CD133+ cells. J. Pharmacol. Exp. Ther.341, 410–423 (2012). CASPubMed Google Scholar
Liu, T. et al. Cucurbitacin B, a small molecule inhibitor of the Stat3 signaling pathway, enhances the chemosensitivity of laryngeal squamous cell carcinoma cells to cisplatin. Eur. J. Pharmacol.641, 15–22 (2010). CASPubMed Google Scholar
Dong, Y. et al. Cucurbitacin E, a tetracyclic triterpenes compound from Chinese medicine, inhibits tumor angiogenesis through VEGFR2-mediated Jak2–STAT3 signaling pathway. Carcinogenesis31, 2097–2104 (2010). CASPubMed Google Scholar
Sun, C. et al. Inhibitory effect of cucurbitacin E on pancreatic cancer cells growth via STAT3 signaling. J. Cancer Res. Clin. Oncol.136, 603–610 (2010). CASPubMed Google Scholar
Huang, W. W. et al. Cucurbitacin E induces G(2)/M phase arrest through STAT3/p53/p21 signaling and provokes apoptosis via Fas/CD95 and mitochondria-dependent pathways in human bladder cancer T24 cells. Evid. Based. Complement. Alternat. Med.2012, 952762 (2012). PubMedPubMed Central Google Scholar
Li, F. et al. Diosgenin, a steroidal saponin, inhibits STAT3 signaling pathway leading to suppression of proliferation and chemosensitization of human hepatocellular carcinoma cells. Cancer Lett.292, 197–207 (2010). CASPubMed Google Scholar
Muto, A. et al. Emodin has a cytotoxic activity against human multiple myeloma as a Janus-activated kinase 2 inhibitor. Mol. Cancer Ther.6, 987–994 (2007). CASPubMed Google Scholar
Badr, G., Mohany, M. & Abu-Tarboush, F. Thymoquinone decreases F-actin polymerization and the proliferation of human multiple myeloma cells by suppressing STAT3 phosphorylation and Bcl2/Bcl-XL expression. Lipids Health Dis.10, 236 (2011). CASPubMedPubMed Central Google Scholar
Li, F., Rajendran, P. & Sethi, G. Thymoquinone inhibits proliferation, induces apoptosis and chemosensitizes human multiple myeloma cells through suppression of signal transducer and activator of transcription 3 activation pathway. Br. J. Pharmacol.161, 541–554 (2010). CASPubMedPubMed Central Google Scholar
Leeman-Neill, R. J. et al. Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors. Clin. Cancer Res.16, 2571–2579 (2010). CASPubMedPubMed Central Google Scholar
Rajendran, P. et al. Honokiol inhibits signal transducer and activator of transcription-3 signaling, proliferation, and survival of hepatocellular carcinoma cells via the protein tyrosine phosphatase SHP-1. J. Cell. Physiol.227, 2184–2195 (2012). CASPubMed Google Scholar
Liu, S. H. et al. Calpain/SHP-1 interaction by honokiol dampening peritoneal dissemination of gastric cancer in nu/nu mice. PLoS ONE7, e43711 (2012). CASPubMedPubMed Central Google Scholar
Yang, J. et al. Evodiamine inhibits STAT3 signaling by inducing phosphatase shatterproof 1 in hepatocellular carcinoma cells. Cancer Lett.325, 243–251 (2013). Google Scholar
Arbiser, J. L. et al. Carbazole is a naturally occurring inhibitor of angiogenesis and inflammation isolated from antipsoriatic coal tar. J. Invest. Dermatol.126, 1396–1402 (2006). CASPubMed Google Scholar
Saturnino, C. et al. Synthesis and biological evaluation of new N-alkylcarbazole derivatives as STAT3 inhibitors: preliminary study. Eur. J. Med. Chem. 60C, 112–119 (2012). CASPubMed Google Scholar
Sun, M. et al. Inhibition of Stat3 activation by sanguinarine suppresses prostate cancer cell growth and invasion. Prostate72, 82–89 (2012). CASPubMed Google Scholar
Kannappan, R., Yadav, V. R. & Aggarwal, B. B. γ-Tocotrienol but not γ-tocopherol blocks STAT3 cell signaling pathway through induction of protein-tyrosine phosphatase SHP-1 and sensitizes tumor cells to chemotherapeutic agents. J. Biol. Chem.285, 33520–33528 (2010). CASPubMedPubMed Central Google Scholar
Rajendran, P. et al. γ-Tocotrienol is a novel inhibitor of constitutive and inducible STAT3 signaling pathway in human hepatocellular carcinoma: potential role as an antiproliferative, pro-apoptotic and chemosensitizing agent. Br. J. Pharmacol.163, 283–298 (2011). CASPubMedPubMed Central Google Scholar
Kunnumakkara, A. B. et al. Boswellic acid blocks signal transducers and activators of transcription 3 signaling, proliferation, and survival of multiple myeloma via the protein tyrosine phosphatase SHP-1. Mol. Cancer Res.7, 118–128 (2009). CASPubMedPubMed Central Google Scholar
Kandala, P. K. & Srivastava, S. K. Regulation of Janus-activated kinase-2 (JAK2) by diindolylmethane in ovarian cancer in vitro and in vivo. Drug Discov. Ther.6, 94–101 (2012). CASPubMed Google Scholar
Chen, X. et al. Brevilin A, a novel natural product, inhibits Janus kinase activity and blocks STAT3 signaling in cancer cells. PLoS ONE8, e63697 (2013). CASPubMedPubMed Central Google Scholar
Leon, M. L. & Zuckerman, S. H. Gamma interferon: a central mediator in atherosclerosis. Inflamm. Res.54, 395–411 (2005). CASPubMed Google Scholar
Zhou, X. X., Gao, P. J. & Sun, B. G. Pravastatin attenuates interferon-γ action via modulation of STAT1 to prevent aortic atherosclerosis in apolipoprotein E-knockout mice. Clin. Exp. Pharmacol. Physiol.36, 373–379 (2009). CASPubMed Google Scholar
Ren, Y. et al. Novel immunomodulatory properties of berbamine through selective down-regulation of STAT4 and action of IFN-γ in experimental autoimmune encephalomyelitis. J. Immunol.181, 1491–1498 (2008). CASPubMed Google Scholar
Nagelkerken, L. Role of Th1 and Th2 cells in autoimmune demyelinating disease. Braz. J. Med. Biol. Res.31, 55–60 (1998). CASPubMed Google Scholar
Lee, B. J. et al. Immunomodulatory effect of water extract of cinnamon on anti-CD3-induced cytokine responses and p38, JNK, ERK1/2, and STAT4 activation. Immunopharmacol. Immunotoxicol.33, 714–722 (2011). CASPubMed Google Scholar
Madan, E. et al. Regulation of apoptosis by resveratrol through JAK/STAT and mitochondria mediated pathway in human epidermoid carcinoma A431 cells. Biochem. Biophys. Res. Commun.377, 1232–1237 (2008). CASPubMed Google Scholar
Muller, J. et al. Discovery of chromone-based inhibitors of the transcription factor STAT5. Chembiochem9, 723–727 (2008). PubMed Google Scholar
Nam, S. et al. Indirubin derivatives induce apoptosis of chronic myelogenous leukemia cells involving inhibition of Stat5 signaling. Mol. Oncol.6, 276–283 (2012). CASPubMedPubMed Central Google Scholar
Stolzenberger, S. Haake, M. & Duschl, A. Specific inhibition of interleukin-4-dependent Stat6 activation by an intracellularly delivered peptide. Eur. J. Biochem.268, 4809–4814 (2001). CASPubMed Google Scholar
McCusker, C. T. et al. Inhibition of experimental allergic airways disease by local application of a cell-penetrating dominant-negative STAT-6 peptide. J. Immunol.179, 2556–2564 (2007). CASPubMed Google Scholar
Wang, Y. et al. Effective treatment of experimental ragweed-induced asthma with STAT-6-IP, a topically delivered cell-penetrating peptide. Clin. Exp. Allergy41, 1622–1630 (2011). CASPubMed Google Scholar
Sakurai, M. et al. TMC-264, a novel inhibitor of STAT6 activation produced by Phoma sp. TC 1674. J. Antibiot.56, 513–519 (2003). CASPubMed Google Scholar
Nagashima, S. et al. Identification of 4-benzylamino-2-[(4-morpholin-4-ylphenyl)amino]pyrimidine-5-carboxamide derivatives as potent and orally bioavailable STAT6 inhibitors. Bioorg. Med. Chem.16, 6509–6521 (2008). CASPubMed Google Scholar
Nagashima, S. et al. Novel 7_H_-pyrrolo[2,3-_d_]pyrimidine derivatives as potent and orally active STAT6 inhibitors. Bioorg. Med. Chem.17, 6926–6936 (2009). CASPubMed Google Scholar
Nakano, T. et al. Niflumic acid suppresses interleukin-13-induced asthma phenotypes. Am. J. Respir. Crit. Care Med.173, 1216–1221 (2006). CASPubMed Google Scholar
Zhou, L. et al. STAT6 phosphorylation inhibitors block eotaxin-3 secretion in bronchial epithelial cells. Bioorg. Med. Chem.20, 750–758 (2012). CASPubMed Google Scholar
Manshouri, T. et al. Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor. Cancer Res.71, 3831–3840 (2011). CASPubMedPubMed Central Google Scholar
Quintas-Cardama, A. et al. Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor. Invest. New Drugs29, 818–826 (2011). CASPubMed Google Scholar
Kantarjian, H. et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med.362, 2260–2270 (2010). CASPubMed Google Scholar
Duensing, A. et al. Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene23, 3999–4006 (2004). CASPubMed Google Scholar
Ravandi, F. et al. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood.116, 2070–2077 (2010). CASPubMedPubMed Central Google Scholar
Nam, S. et al. Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells. Mol. Cancer Ther.6, 1400–1405 (2007). CASPubMed Google Scholar
Quentmeier, H. et al. BCR–ABL1-independent PI3Kinase activation causing imatinib-resistance. J. Hematol. Oncol.4, 6 (2011). CASPubMedPubMed Central Google Scholar
Pallis, A. G. & Syrigos, K. N. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC. Lung Cancer80, 120–130 (2013). CASPubMed Google Scholar
Leeman-Neill, R. J. et al. Inhibition of EGFR–STAT3 signaling with erlotinib prevents carcinogenesis in a chemically-induced mouse model of oral squamous cell carcinoma. Cancer Prev. Res. (Phila)4, 230–237 (2011). CAS Google Scholar
Bachawal, S. V., Wali, V. B. & Sylvester, P. W. Combined γ-tocotrienol and erlotinib/gefitinib treatment suppresses Stat and Akt signaling in murine mammary tumor cells. AnticancerRes.30, 429–437 (2010). CAS Google Scholar
Cheng, A. L. et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol.10, 25–34 (2009). CASPubMed Google Scholar
Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med.359, 378–390 (2008). CASPubMed Google Scholar
Yang, Y. et al. The monoclonal antibody CH12 enhances the sorafenib-mediated growth inhibition of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III. Neoplasia14, 509–518 (2012). PubMedPubMed Central Google Scholar
Yang, F. et al. Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3. Mol. Cancer Ther.9, 953–962 (2010). CASPubMedPubMed Central Google Scholar
Yang, F. et al. Sorafenib inhibits endogenous and IL-6/S1P induced JAK2–STAT3 signaling in human neuroblastoma, associated with growth suppression and apoptosis. Cancer Biol. Ther.13, 534–541 (2012). CASPubMed Google Scholar
Tai, W. T. et al. Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. J. Hepatol.55, 1041–1048 (2011). CASPubMed Google Scholar
Chen, K. F. et al. Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody. Br. J. Pharmacol.168, 658–672 (2013). CASPubMedPubMed Central Google Scholar
Chen, K. F. et al. Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity. Eur. J. Med. Chem.55, 220–227 (2012). CASPubMed Google Scholar
Pedranzini, L. et al. Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells. Cancer Res.66, 9714–9721 (2006). CASPubMed Google Scholar
Nelson, E. A. et al. Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3. Blood112, 5095–5102 (2008). CASPubMedPubMed Central Google Scholar
Muhammad, S. et al. The role of EGFR monoclonal antibodies (MoABs) cetuximab/panitumab, and BRAF inhibitors in BRAF mutated colorectal cancer. J. Gastrointest Oncol.4, 72–81 (2013). CASPubMedPubMed Central Google Scholar
Patel, D. et al. Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation. Int. J. Oncol.34, 25–32 (2009). CASPubMed Google Scholar
Gravalos, C. et al. Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer. Clin. Transl. Oncol.13, 179–184 (2011). CASPubMed Google Scholar
Kim, S. Y. et al. Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. Int. J. Oncol.32, 89–95 (2008). PubMed Google Scholar
Migita, K. et al. Inhibitory effects of the JAK inhibitor CP690,550 on human CD4+ T lymphocyte cytokine production. BMC Immunol.12, 51 (2011). CASPubMedPubMed Central Google Scholar
Quintas-Cardama, A. et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood115, 3109–3117 (2010). CASPubMedPubMed Central Google Scholar
Looyenga, B. D. et al. STAT3 is activated by JAK2 independent of key oncogenic driver mutations in non-small cell lung carcinoma. PLoS ONE7, e30820 (2012). CASPubMedPubMed Central Google Scholar
Derenzini, E. et al. The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma. Blood Cancer J.1, e46 (2011). CASPubMedPubMed Central Google Scholar
Hedvat, M. et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell.16, 487–497 (2009). CASPubMedPubMed Central Google Scholar
McFarland, B. C. et al. Therapeutic potential of AZD1480 for the treatment of human glioblastoma. Mol. Cancer Ther.10, 2384–2393 (2011). CASPubMedPubMed Central Google Scholar
Xin, H. et al. Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480. Cancer Res.71, 6601–6610 (2011). CASPubMedPubMed Central Google Scholar
Faderl, S. et al. Atiprimod blocks phosphorylation of JAK–STAT and inhibits proliferation of acute myeloid leukemia (AML) cells. Leuk. Res.31, 91–95 (2007). CASPubMed Google Scholar
Amit-Vazina, M. et al. Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells. Br. J. Cancer.93, 70–80 (2005). CASPubMedPubMed Central Google Scholar
Kim, N. H. et al. Auranofin blocks interleukin-6 signaling by inhibiting phosphorylation of JAK1 and STAT3. Immunology122, 607–614 (2007). CASPubMedPubMed Central Google Scholar
Nakaya, A. et al. The gold compound auranofin induces apoptosis of human multiple myeloma cells through both down-regulation of STAT3 and inhibition of NF-κB activity. Leuk. Res.35, 243–249 (2011). CASPubMed Google Scholar
Song, L. et al. Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res.66, 5542–5548 (2006). CASPubMed Google Scholar
Song, L. et al. JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling. Mol. Cancer Ther.10, 481–494 (2011). CASPubMedPubMed Central Google Scholar
Sen, M. et al. First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy. Cancer Discov.2, 694–705 (2012). This is the first-in-human study of a STAT3-selective inhibitor, which is a transcription factor decoy. CASPubMedPubMed Central Google Scholar
Souissi, I. et al. A STAT3-inhibitory hairpin decoy oligodeoxynucleotide discriminates between STAT1 and STAT3 and induces death in a human colon carcinoma cell line. Mol. Cancer11, 12 (2012). CASPubMedPubMed Central Google Scholar
Huckel, M. et al. Attenuation of murine antigen-induced arthritis by treatment with a decoy oligodeoxynucleotide inhibiting signal transducer and activator of transcription-1 (STAT-1). Arthritis Res. Ther.8, R17 (2006). PubMed Google Scholar
Stadlbauer, T. H. et al. AP-1 and STAT-1 decoy oligodeoxynucleotides attenuate transplant vasculopathy in rat cardiac allografts. Cardiovasc. Res.79, 698–705 (2008). CASPubMed Google Scholar
Wang, X. et al. Targeted blockage of signal transducer and activator of transcription 5 signaling pathway with decoy oligodeoxynucleotides suppresses leukemic K562 cell growth. DNA Cell Biol.30, 71–78 (2011). PubMedPubMed Central Google Scholar
Shen, J., Li, R. & Li, G. Inhibitory effects of decoy-ODN targeting activated STAT3 on human glioma growth in vivo. In Vivo23, 237–243 (2009). CASPubMed Google Scholar
Sen, M. et al. Targeting Stat3 abrogates EGFR inhibitor resistance in cancer. Clin. Cancer Res.18, 4986–4996 (2012). CASPubMedPubMed Central Google Scholar
Lui, V. W. et al. Antiproliferative mechanisms of a transcription factor decoy targeting signal transducer and activator of transcription (STAT) 3: the role of STAT1. Mol. Pharmacol.71, 1435–1443 (2007). CASPubMed Google Scholar
Niu, G. et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene21, 2000–2008 (2002). CASPubMed Google Scholar
Barton, B. E. et al. Novel single-stranded oligonucleotides that inhibit signal transducer and activator of transcription 3 induce apoptosis in vitro and in vivo in prostate cancer cell lines. Mol. Cancer Ther.3, 1183–1191 (2004). CASPubMed Google Scholar
Li, W. C. et al. Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3. Clin. Cancer Res.12, 7140–7148 (2006). CASPubMed Google Scholar
Burel, S. A. et al. Preclinical evaluation of the toxicological effects of a novel constrained ethyl modified antisense compound targeting signal transducer and activator of transcription 3 in mice and cynomolgus monkeys. Nucleic Acid. Ther.23, 213–227 (2013). CASPubMed Google Scholar